Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 128 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Androgen-Independent Prostatic Cancer Clear all
Completed Phase 2 Interventional

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011
View directory record Official record
Conditions
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Interventions
lorigerlimab, docetaxel, Prednisone
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 9:22 AM EDT
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615
View directory record Official record
Conditions
Hormone-refractory Prostate Cancer
Interventions
VIR-5500, Androgen receptor signaling inhibitor (ARSI), Docetaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

NCT00014352
View directory record Official record
Conditions
Prostate Cancer, Thromboembolism
Interventions
docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, ketoconazole, warfarin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 22, 2026, 9:22 AM EDT
Not listed Phase 2 Interventional

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

NCT00285675
View directory record Official record
Conditions
Androgen Independent Prostate Cancer (AIPC), Non Small Cell Lung Cancer (NSCLC)
Interventions
DN-101 (calcitriol) - Drug
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Berkeley, California • San Francisco, California • Vallejo, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 31, 2006 · Synced Oct 22, 2026, 9:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00471718
View directory record Official record
Conditions
Prostate Cancer
Interventions
ABT-751
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

NCT00065442
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sipuleucel-T, APC-Placebo
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
65
States / cities
Laguna Hills, California • Loma Linda, California • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2010 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional

MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

NCT00070837
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MLN2704 (DM1 conjugated monoclonal antibody MLN591)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
New York, New York • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2007 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

NCT00003084
View directory record Official record
Conditions
Prostate Cancer
Interventions
Doxorubicin Hydrochloride, Estramustine phosphate sodium, Etoposide, Ketoconazole, Paclitaxel, Vinblastine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 22, 2026, 9:22 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

NCT00121095
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Samarium Sm-153 lexidronam + Docetaxel
Drug
Lead sponsor
Cytogen Corporation
Industry
Eligibility
Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

NCT00919035
View directory record Official record
Conditions
Prostate Cancer
Interventions
torisel
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Niles, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

NCT00307294
View directory record Official record
Conditions
Prostate Cancer
Interventions
Thalidomide, Doxil
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

NCT00084825
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

NCT01378091
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lenalidomide, Docetaxel, Prednisone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Lycopene in Treating Patients With Metastatic Prostate Cancer

NCT00068731
View directory record Official record
Conditions
Prostate Cancer
Interventions
lycopene
Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 22, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

Sandostatin for Patients With Androgen Independent Prostate Cancer

NCT00510224
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sandostatin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00038194
View directory record Official record
Conditions
Prostate Cancer
Interventions
imatinib mesylate, docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 22, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

NCT00780975
View directory record Official record
Conditions
Prostate Cancer
Interventions
Aplidin (plitidepsin)
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer

NCT00134654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Premarin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

NCT00272038
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tarceva
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Fulvestrant in Treating Patients With Advanced Prostate Cancer

NCT00244998
View directory record Official record
Conditions
Prostate Cancer
Interventions
fulvestrant
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 22, 2026, 9:22 AM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06033001
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer
Interventions
[Lu-177]-PNT2002
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
U.S. locations
7
States / cities
Newport Beach, California • Hartford, Connecticut • Jupiter, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 22, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080782
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Celecoxib, Doxorubicin Hydrochloride, Strontium chloride Sr 89
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere

NCT00274287
View directory record Official record
Conditions
Prostate Cancer
Interventions
GM CSF
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 22, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

NCT00110188
View directory record Official record
Conditions
Prostate Cancer
Interventions
ridaforolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 22, 2026, 9:22 AM EDT